Concentrations of these metabolites were measured with liquid chromatography and mass spectrometry[50] and a higher kynurenine to tryptophan ratio and quinolinic acid at baseline, resulting from IDO metabolic activity, was found in plasma samples of NSCLC patients with early progression under Nivolumab treatment. Here, IDO1 is linked to non-small cell lung carcinoma.